CONATUS PHARMACEUTICALS INC. (NASDAQ:CNAT) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On May 4, 2017, Conatus Pharmaceuticals Inc. issued a press
release announcing its financial results for the quarter ended
March 31, 2017. A copy of the press release is attached hereto as
Exhibit 99.1 and is incorporated herein by reference.
In accordance with General Instruction B.2. of Form 8-K, the
information in this Item 2.02, including Exhibit 99.1, shall not
be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liabilities of that Section, nor shall it be
deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description |
| 99.1 | Press release issued on May 4, 2017 |
About CONATUS PHARMACEUTICALS INC. (NASDAQ:CNAT)
Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation. CONATUS PHARMACEUTICALS INC. (NASDAQ:CNAT) Recent Trading Information
CONATUS PHARMACEUTICALS INC. (NASDAQ:CNAT) closed its last trading session down -0.38 at 7.73 with 527,937 shares trading hands.